Tag: Laboratory Tests

  • Diagnostic Procedures that Complement and Supplement Laboratory Tests

    The clinical pathologist frequently encounters situations in which laboratory tests alone are not sufficient to provide a diagnosis. If this happens, certain diagnostic procedures may be suggested to provide additional information. These procedures are noted together with the laboratory tests that they complement or supplement. Nevertheless, it seems useful to summarize some basic information about these techniques and some data that, for various reasons, are not included elsewhere.

    Diagnostic ultrasound

    Ultrasound is based on the familiar principle of radar, differing primarily in the frequency of the sound waves. Very high-frequency (1-10 MHZ) sound emissions are directed toward an object, are reflected (echo production) by the target, and return to the detector, with a time delay proportional to the distance traveled. Differences in tissue or substance density result in a series of echoes produced by the surfaces of the various tissues or substances that lie in the path of the sound beam.

    In A-mode (amplitude) readout, the echo signals are seen as spikes (similar to an electrocardiogram [ECG] tracing format) with the height of the spike corresponding to the intensity of the echo and the distance between spikes depending on the distance between the various interfaces (boundaries) of substances in the path of the sound beam. The A-mode technique is infrequently used today, but early in the development of ultrasound it was often used to examine the brain, since the skull prevented adequate B-mode (brightness-modulated, bistable) visualization.

    In B-mode readout, the sonic generator (transducer) is moved in a line across an area while the echoes are depicted as tiny dots corresponding to the location (origin) of the echo. This produces a pattern of dots, which gives a visual image of the shape and degree of homogeneity of material in the path of the sound beam (the visual result is a tomographic slice or thin cross-section of the target, with a dot pattern form somewhat analogous to that of a nuclear medicine scan).

    Gray-scale mode is a refinement of B-mode scan readout in which changes in amplitude (intensity) of the sonic beam produced by differential absorption through different substances in the path of the beam are converted to shades of gray in the dot pattern. This helps the observer recognize smaller changes in tissue density (somewhat analogous to an x-ray).

    B-mode ultrasound (including gray-scale) is now the basic technique for most routine work. Limitations include problems with very dense materials that act as a barrier both to signal and to echo (e.g., bone or x-ray barium), and air, which is a poor transmitter of high-frequency sound (lungs, air in distended bowel or stomach, etc.).

    In M-mode (motion) readout, the sonic generator and detector remain temporarily in one location, and each echo is depicted as a small dot relative to original echo location; this is similar to A mode, but it uses a single dot instead of a spike. However, a moving recorder shows changes in the echo pattern that occur if any structures in the sonic beam path move; changes in location of the echo dot are seen in the areas that move but not in the areas that are stationary. The result is a series of parallel lines, each line corresponding to the continuous record of one echo dot; stationary dots produce straight lines and moving dots become a wavy or ECG-like line. In fact, the technique and readout are somewhat analogous to those of the ECG, if each area of the heart were to produce its own ECG tracing and all were displayed together as a series of parallel tracings. The M-mode technique is used primarily in studies of the heart (echocardiography), particularly aortic and mitral valve function.

    Real-time ultrasound is designed to provide a picture similar to B-mode ultrasound but that is obtained rapidly enough to capture motion changes. Theoretically, real-time means that the system is able to evaluate information as soon as it is received rather than storing or accumulating any data. This is analogous to a fluoroscope x-ray image compared to a conventional x-ray. M-mode ultrasound produces single-dimension outlines of a moving structure as it moves or changes shape, whereas real-time two-dimensional ultrasound produces an image very similar to that produced by a static B-mode scanner but much more rapidly (15-50 frames/second)—fast enough to provide the impression of motion when the various images obtained are viewed rapidly one after the other (either by direct viewing as they are obtained on a cathode ray tube (CRT) screen or as they are recorded and played back from magnetic tape or similar recording device). At present the equipment available to accomplish this exists in two forms: a linear array of crystals, the crystals being activated in sequence with electronic steering of the sound beam; and so-called small contact area (sector) scanners, having either an electronically phased crystal array or several crystals that are rotated mechanically. A triangular wedge-shaped image is obtained with the sector scanner and a somewhat more rectangular image with the linear-array scanner, both of which basically resemble images produced by a static B-mode scanner. On sector scanning, the apex of the triangle represents the ultrasound transducer (the sound wave generator and receiving crystal). The field of view (size of the triangle) of a typical real-time sector scanner is smaller than that of a standard static B-mode scanner (although the size differential is being decreased by new technology). Real-time image quality originally was inferior to that of static equipment, but this too has changed. Real-time equipment in general is less expensive, more compact, and more portable than static equipment; the ultrasound transducer is usually small and hand held and is generally designed to permit rapid changes in position to scan different areas rapidly using different planes of orientation. Many ultrasonographers now use real-time ultrasound as their primary ultrasound technique.

    Uses of diagnostic ultrasound. With continuing improvements in equipment, capabilities of ultrasound are changing rapidly. A major advantage is that ultrasound is completely noninvasive; in addition, no radiation is administered, and no acute or chronic ill effects have yet been substantiated in either tissues or genetic apparatus. The following sections describe some of the major areas in which ultrasound may be helpful.

    Differentiation of solid from cystic structures. This is helpful in the diagnosis of renal space-occupying lesions, nonfunctioning thyroid nodules, pancreatic pseudocyst, pelvic masses, and so on. When a structure is ultrasonically interpreted as a cyst, accuracy should be 90%-95%. Ultrasound is the best method for diagnosis of pancreatic pseudocyst.

    Abscess detection. In the abdomen, reported accuracy (in a few small series) varies between 60% and 90%, with 80% probably a reasonable present-day expectation. Abscess within organs such as the liver may be seen and differentiated from a cyst or solid tumor. Obvious factors affecting accuracy are size and location of the abscess, as well as interference from air or barium in overlying bowel loops.

    Differentiation of intrahepatic from extrahepatic biary obstruction. This is based on attempted visualization of common bile duct dilatation in extrahepatic obstruction. Current accuracy is probably about 80%-90%.

    Ultrasound may be useful in demonstrating a dilated gallbladder when cholecystography is not possible or suggests nonfunction. It may also be helpful in diagnosis of cholecystitis. Reports indicate about 90%-95% accuracy in detection of gallbladder calculi or other significant abnormalities. Some medical centers advocate a protocol in which single-dose oral cholecystography is done first; if the gallbladder fails to visualize, ultrasonography is performed. Detection of stones would make double-dose oral cholecystography unnecessary. Some are now using ultrasound as the primary method of gallbladder examination.

    Diagnosis of pancreatic carcinoma. Although islet cell tumors are too small to be seen, acinar carcinoma can be detected in approximately 75%-80% of instances. Pancreatic carcinoma cannot always be differentiated from pancreatitis. In the majority of institutions where computerized tomography (CT) is available, CT is preferred to ultrasound. CT generally provides better results in obese patients, and ultrasound usually provides better results in very thin patients.

    Guidance of biopsy needles. Ultrasound is helpful in biopsies of organs such as the kidney.

    Placental localization. Ultrasound is the procedure of choice for visualization of the fetus (fetal position, determination of fetal age by fetal measurements, detection of fetal anomalies, detection of fetal growth retardation), visualization of intrauterine or ectopic pregnancy, and diagnosis of hydatidiform mole. Ultrasound is the preferred method for direct visualization in obstetrics to avoid irradiation of mother or fetus.

    Detection and delineation of abdominal aortic aneurysms. Ultrasound is the current method of choice for these aneurysms. Clot in the lumen, which causes problems for aortography, does not interfere with ultrasound. For dissecting abdominal aneurysms, however, ultrasound is much less reliable than aortography. Thoracic aneurysms are difficult to visualize by ultrasound with present techniques; esophageal transducers may help.

    Detection of periaortic and retroperitoneal masses of enlarged lymph nodes. Ultrasound current accuracy is reported to be 80%-90%. However, CT has equal or better accuracy, and is preferred in many institutions because it visualizes the entire abdomen.

    Ocular examinations. Although special equipment is needed, ultrasound has proved useful for detection of intraocular foreign bodies and tumors, as well as certain other conditions. This technique is especially helpful when opacity prevents adequate visual examination.

    Cardiac diagnosis. Ultrasound using M-mode technique is the most sensitive and accurate method for detection of pericardial effusion, capable of detecting as little as 50 ml of fluid. A minor drawback is difficulty in finding loculated effusions. Mitral stenosis can be diagnosed accurately, and useful information can be obtained about other types of mitral dysfunction. Ultrasound can also provide information about aortic and tricuspid function, although not to the same degree as mitral valve studies. Entities such as hypertrophic subaortic stenosis and left atrial myxoma can frequently be identified. The thickness of the left ventricle can be estimated. Finally, vegetations of endocarditis may be detected on mitral, aortic, or tricuspid valves in more than one half of patients. Two-dimensional echocardiography is real-time ultrasound. It can perform most of the same functions as M-mode ultrasound, but in addition it provides more complete visualization of congenital heart defects and is able to demonstrate left ventricle heart wall motion or structural abnormalities in about 70%-80% of patients.

    Doppler ultrasound is a special variant that can image blood flow. The Doppler effect is the change in ultrasound sound wave frequency produced when ultrasonic pulses are scattered by RBCs moving within a blood vessel. By moving the transducer along the path of a blood vessel, data can be obtained about the velocity of flow in areas over which the transducer moves. Most current Doppler equipment combines Doppler signals with B-mode ultrasonic imaging (“duplex scanning”). The B-mode component provides a picture of the vessel, whereas the Doppler component obtains flow data in that segment of the vessel. This combination is used to demonstrate areas of narrowing, obstruction, or blood flow turbulence in the vessel.

    Computerized tomography (CT)

    Originally known as computerized axial tomography (CAT), CT combines radiologic x-ray emission with nuclear medicine-type radiation detectors (rather than direct x-ray exposure of photographic film in the manner of ordinary radiology). Tissue density of the various components of the object or body part being scanned determines how much of the electron beam reaches the detector assembly, similar to conventional radiology. The original machines used a pencil-like x-ray beam that had to go back and forth over the scanning area, with each track being next to the previous one. Current equipment is of two basic types. Some manufacturers use a fan-shaped (triangular) beam with multiple gas-filled tube detectors on the opposite side of the object to be scanned (corresponding to the base of the x-ray beam triangle). The beam source and the multiple detector segment move at the same time and speed in a complete 360-degree circle around the object to be scanned. Other manufacturers use a single x-ray source emitting a fan-shaped beam that travels in a circle around the object to be scanned while outside of the x-ray source path is a complete circle of nonmoving detectors. In all cases a computer secures tissue density measurements from the detector as this is going on and eventually constructs a composite tissue density image similar in many aspects to those seen in ordinary x-rays. The image corresponds to a thin cross-section slice through the object (3-15 mm thick), in other words, a tissue cross-section slice viewed at a right angle (90 degrees) to the direction of the x-ray beam.

    CT scan times necessary for each tissue slice vary with different manufacturers and with different models from the same manufacturer. The original CT units took more than 30 seconds per slice, second-generation CT units took about 20 seconds per slice, whereas current models can operate at less than 5 seconds per slice.

    CT is currently the procedure of choice in detection of space-occupying lesions of the CNS. It is also very important (the procedure of choice for some) in detecting and delineating mass lesions of the abdomen (tumor, abscess, hemorrhage, etc.), mass lesions of organs (e.g., lung, adrenals or pancreas) and retroperitoneal adenopathy. It has also been advocated for differentiation of extrahepatic versus intrahepatic jaundice (using the criterion of a dilated common bile duct), but ultrasound is still more commonly used for this purpose due to lower cost, ease of performance, and scheduling considerations.

    Nuclear medicine scanning

    Nuclear medicine organ scans involve certain compounds that selectively localize in the organs of interest when administered to the patient. The compound is first made radioactive by tagging with a radioactive element. An exception is iodine used in thyroid diagnosis, which is already an element; in this case a radioactive isotope of iodine can be used. An isotope is a different form of the same element with the same chemical properties as the stable element form but physically unstable due to differences in the number of neutrons in the nucleus, this difference producing nuclear instability and leading to emission of radioactivity. After the radioactive compound is administered and sufficient uptake by the organ of interest is achieved, the organ is “scanned” with a radiation detector. This is usually a sodium iodide crystal. Radioactivity is transmuted into tiny flashes of light within the crystal. The location of the light flashes corresponds to the locations within the organ from which radioactivity is being emitted; the intensity of a light flash is proportional to the quantity of radiation detected. The detection device surveys (scans) the organ and produces an overall pattern of radioactivity (both the concentration and the distribution of activity), which it translates into a visual picture of light and dark areas.

    Rectilinear scanners focus on one small area; the detector traverses the organ in a series of parallel lines to produce a complete (composite) picture. A “camera” device has a large-diameter crystal and remains stationary, with the field of view size dependent on the size of the crystal. The various organ scans are discussed in chapters that include biochemical function tests referable to the same organ.

    The camera detectors are able to perform rapid-sequence imaging not possible on a rectilinear apparatus, and this can be used for “dynamic flow” studies. A bolus of radioactive material can be injected into the bloodstream and followed through major vessels and organs by data storage equipment or rapid (1- to 3-second) serial photographs. Although the image does not have a degree of resolution comparable to that of contrast medium angiography, major abnormalities in major blood vessels can be identified, and the uptake and early distribution of blood supply in specific tissues or organs can be visualized.

    Data on radionuclide procedures are included in areas of laboratory test discussion when this seems appropriate.

    Magnetic resonance imaging (MR or MRI)

    Magnetic resonance (MR; originally called nuclear magnetic resonance) is the newest imaging process. This is based on the fact that nuclei of many chemical elements (notably those with an uneven number of protons or neutrons such as 1H or 31P) spin (“precess”) around a central axis. If a magnetic field is brought close by (using an electromagnet) the nuclei, still spinning, line up in the direction of the magnetic field. A new rate of spin (resonant frequency) will be proportional to the characteristics of the nucleus, the chemical environment, and the strength of the magnetic field. If the nuclei are then bombarded with an energy beam having the frequency of radio waves at a 90-degree angle to the electromagnetic field, the nuclei are pushed momentarily a little out of line. When the exciting radiofrequency energy is terminated, the nuclei return to their position in the magnetic field, giving up some energy. The energy may be transmitted to their immediate environment (called the “lattice,” the time required to give up the energy and return to position being called the “spin-lattice relaxation time,” or T1), or may be transmitted to adjacent nuclei of the same element, thus providing a realignment response of many nuclei (called “spin-spin relaxation time,” or T2). The absorption of radiofrequency energy can be detected by a spectrometer of special design. Besides differences in relaxation time, differences in proton density can also be detected and measured. MR proton density or relaxation time differs for different tissues and is affected by different disease processes and possibly by exogenous chemical manipulation. The instrumentation can produce computer-generated two-dimensional cross-section images of the nuclear changes that look like CT scans of tissue. Thus, MR can detect anatomical structural abnormality and changes in normal tissue and potentially can detect cellular dysfunction at the molecular level. Several manufacturers are producing MR instruments, which differ in the type and magnetic field strength of electromagnets used, the method of inducing disruptive energy into the magnetic field, and the method of detection and processing of results. Unlike CT, no radiation is given to the patient.

  • Laboratory Tests in Psychiatry

    Until recently, the laboratory had relatively little to offer in psychiatry. Laboratory tests were used mainly to diagnose or exclude organic illness. For example, in one study about 5% of patients with dementia had organic diseases such as hyponatremia, hypothyroidism, hypoglycemia, and hypercalcemia; about 4% were caused by alcohol; and about 10% were due to toxic effects of drugs. A few psychiatric drug blood level assays were available, of which lithium was the most important. In the 1970s, important work was done suggesting that the neuroendocrine system is involved in some way with certain major psychiatric illnesses. Thus far, melancholia (endogenous psychiatric depression or primary depression) is the illness in which neuroendocrine abnormality has been most extensively documented. It was found that many such patients had abnormal cortisol blood levels that were very similar to those seen in Cushing’s syndrome (as described in the chapter on adrenal function) without having the typical signs and symptoms of Cushing’s syndrome. There often was blunting or abolition of normal cortisol circadian rhythm, elevated urine free cortisol excretion levels, and resistance to normally expected suppression of cortisol blood levels after a low dose of dexamethasone.

    Because of these observations, the low-dose overnight dexamethasone test, used to screen for Cushing’s syndrome, has been modified to screen for melancholia. One milligram of oral dexamethasone is given at 11 P.M., and blood is drawn for cortisol assay on the following day at 4 P.M. and 11 P.M. Normally, serum cortisol levels should be suppressed to less than 5 µg/100 ml (138 nmol/L) in both specimens. An abnormal result consists of failure to suppress in at least one of the two specimens (about 20% of melancholia patients demonstrate normal suppression in the 4 P.M. specimen but no suppression in the 11 P.M. specimen, and about the same number of patients fail to suppress in the 4 P.M. specimen but have normal suppression in the 11 P.M. sample). The psychiatric dexamethasone test is different from the dexamethasone test for Cushing’s syndrome, because in the Cushing protocol a single specimen is drawn at 8 A.M. in the morning after dexamethasone administration.

    The Cushing’s disease protocol is reported to detect only about 25% of patients with melancholia, in contrast to the modified two-specimen psychiatric protocol, which is reported to detect up to 58%. Various investigators using various doses of dexamethasone and collection times have reported a detection rate of about 45% (literature range, 24%-100%). False positive rates using the two-specimen protocol are reported to be less than 5%. Since some patients with Cushing’s syndrome may exhibit symptoms of psychiatric depression, differentiation of melancholia from Cushing’s syndrome becomes necessary if test results show nonsuppression of serum cortisol. The patient is given appropriate antidepressant therapy and the test is repeated. If the test result becomes normal, Cushing’s syndrome is virtually excluded.

    Various conditions not associated with either Cushing’s syndrome or melancholia can affect cortisol secretion patterns. Conditions that must be excluded to obtain a reliable result include severe major organic illness of any type, recent electroshock therapy, trauma, severe weight loss, malnutrition, alcoholic withdrawal, pregnancy, Addison’s disease, and pituitary deficiency. Certain medications such as phenobarbital, phenytoin (Dilantin), steroid therapy, or estrogens may produce falsely abnormal results.

    At present, there is considerable controversy regarding the usefulness of the modified low-dose dexamethasone test for melancholia, since the test has a sensitivity no greater than 50% and significant potential for false positive results.

    Besides the overnight modified low-dose dexamethasone test, the thyrotropin-releasing hormone (TRH) test has been reported to be abnormal in about 60% of patients with primary (unipolar) depression. Abnormality consists of a blunted (decreased) thyrotropin-stimulating hormone response to administration of TRH, similar to the result obtained in hyperthyroidism or hypopituitarism. However, occasionally patients with melancholia have hypothyroidism, which produces an exaggerated response in the TRH test rather than a blunted (decreased) response.

    One investigator found that about 30% of patients with melancholia had abnormal results on both the TRH and the modified dexamethasone tests. About 30% of the patients had abnormal TRH results but normal dexamethasone responses, and about 20% had abnormal dexamethasone responses but normal TRH responses. The TRH test has not been investigated as extensively as the modified dexamethasone test.

    A more controversial area is measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in patients with depression. One theory links depression to a functional deficiency of norepinephrine in the central nervous system (CNS). 3-Methoxy-4-hydroxyphenylglycol is a major metabolite of norepinephrine. It is thought that a significant part of urinary MHPG is derived from CNS sources (20%-63% in different studies). Some studies indicated that depressed patients had lower urinary (24-hour) excretion of MHPG than other patients, and that patients in the manic-phase of bipolar (manic-depressive) illness had increased MHPG levels. There was also some evidence that depressed patients with subnormal urinary MHPG levels responded better to tricyclic antidepressants such as imipramine than did patients with normal urine MHPG levels. However, these findings have been somewhat controversial and have not been universally accepted.

  • Congenital Diseases of Skeletal Muscle

    Several well-known disorders affecting skeletal muscle either are not congenital or do not yet have any conspicuously useful laboratory test. Among these are disorders whose primary defect is located in the central nervous system or peripheral nervous system rather than in skeletal muscle itself. In this group are various neurologic diseases that secondarily result in symptoms of muscle weakness. The following discussion involves inherited muscle disorders. Some can be diagnosed in the first trimester of pregnancy by means of amniotic villus biopsy.

    Muscular dystrophies. The muscular dystrophies can be divided into several subgroups. The most common is Duchenne’s (pseudohypertrophic) dystrophy. Duchenne’s muscular dystrophy and the closely related Becker’s muscular dystrophy is transmitted as a familial sex-linked recessive disorder in 60%-65% of cases and is said to be the most common lethal sex-linked genetic disease. As in all sex-linked genetic diseases, the X chromosome carriers the abnormal gene. In Duchenne’s dystrophy this gene controls production of dystrophin, a protein found in skeletal, cardiac, and smooth muscle at the muscle fiber outer membrane, where it apparently helps provide strength and elasticity to the muscle fiber. Although both males and females may have the defective gene, females rarely develop clinical symptoms. About one third of cases are sporadic gene mutations. The male patient is clinically normal for the first few months of life; symptoms develop most often between ages 1 and 6 years. The most frequent symptoms are lower extremity and pelvic muscle weakness. There is spotty but progressive muscle fiber dissolution, with excessive replacement by fat and fibrous tissue. The latter process leads to the most characteristic physical finding of the disease, pseudohypertrophy of the calf muscles.

    Laboratory tests. Screening tests are based on the fact that certain enzymes are found in relatively high amounts in normal skeletal muscle. These include creatine phosphokinase, aldolase, aspartate aminotransferase (AST), and lactic dehydrogenase (LDH). Despite external pseudohypertrophy, the dystrophic muscles actually undergo individual fiber dissolution and loss of skeletal muscle substance, accompanied by release of muscle enzymes into the bloodstream. In many tissues AST, LDH, and aldolase are found together. Pulmonary infarction, myocardial infarction, and acute liver cell damage among other conditions cause elevated serum levels of these enzymes. Aldolase follows a pattern similar to AST in liver disease and to LDH otherwise. Creatine Kinase (previously creatine phosphokinase) or CK is found in significant concentration only in brain, heart muscle, and skeletal muscle.

    The two most helpful tests in Duchenne’s muscular dystrophy are CK and aldolase assays. Aldolase and CK values are elevated very early in the disease, well before clinical symptoms become manifest, and the elevations usually are more than 10 times normal, at least for CK. This marked elevation persists as symptoms develop. Eventually, after replacement of muscle substance has become chronic and extensive, the aldolase level often becomes normal and the CK level may be either normal or only mildly elevated (less than 5 times normal). In the hereditary type of Duchenne’s dystrophy, most males with the abnormal gene have elevated CK values. In females with the abnormal gene, about 50%-60% have elevated CK. Aldolase values are much less frequently abnormal; AST and LDH values tend to parallel CK and aldolase values but at a much lower level. Therefore, other than CK, these enzymes are not of much use in detecting carriers. Even with CK, a normal result does not exclude carrier status.

    The CK isoenzyme pattern in Duchenne’s dystrophy may show an increased MB isoenzyme as well as MM fraction, especially in the earlier phases of the illness.

    In fascioscapulohumeral dystrophy and limbgirdle dystrophy, conditions that resemble Duchenne’s dystrophy in many respects, CK and aldolase levels are variable but frequently are normal.

    Other muscular disorders in which the serum enzyme levels may be elevated are trauma, dermatomyositis, and polymyositis. The levels of elevation are said to be considerably below those seen in early cases of Duchenne’s dystrophy. Neurologic disease is usually not associated with elevated levels, even when there is marked secondary muscular atrophy.

    Definitive diagnosis. Diagnosis of the muscular dystrophies may sometimes be made on the basis of the clinical picture and enzyme values. A more definitive diagnosis can be made with the addition of muscle biopsy. This becomes essential when the findings are not clear cut. The biceps or quadriceps muscles are the preferred biopsy location. The biopsy is best done at a pediatric or congenital disease research center where special studies (e.g., histochemical staining or electron microscopy) can be performed and the proper specimen secured for this purpose (these special studies provide additional information and are essential when biopsy results are atypical or yield unexpected findings). Biopsy specimens show greatly decreased dystrophin on assay or essentially absent dystrophin on tissue sections stained with antidystrophin antibody. In Becker’s dystrophy, dystrophin is present in tissue sections but considerably reduced. Another diagnostic method is DNA probe. About two thirds of Duchenne’s and Becker’s cases are due to partial deletion from the dystrophin gene. These cases can be diagnosed by standard DNA probe. The 35% without detectable deletion can be tested for with the restriction length polymorphism DNA probe method, which is less accurate than gene deletion DNA methods. Diagnosis in the first trimester of pregnancy can be done using DNA probe techniques on a chorionic villus biopsy specimen.

    Malignant hyperpyrexia (MH) Malignant hyperpyrexia (MH) is a rare complication of anesthesia triggered by various conduction and inhalation agents (most commonly succinylcholine) that produces a marked increase in both aerobic and anaerobic skeletal muscle metabolism. This results in greatly increased production of carbon dioxide, lactic acid, and heat. Such overproduction, in turn, is clinically manifested by a marked increase in body temperature, tachycardia, muscle rigidity, tachypnea, and finally shock. The first clinical sign is said to be muscle rigidity, which occurs in about 70%-75% of patients. The next clinical evidence of developing MH is tachycardia or cardiac ventricular multifocal arrhythmias. A rise in temperature eventually occurs in nearly all patients (some cases have been reported without temperature elevation), first slowly and then rapidly. The characteristic temperature elevation may not be present in the early stages, or the initial elevation may be gradual. A defect in muscle cell membrane calcium release mechanism (“calcium channel”) has been postulated, leading to increased intracellular calcium. The majority of cases have been familial. There is frequent association with various hereditary muscle diseases, especially the muscular dystrophies.

    Laboratory tests. Biochemical abnormalities include metabolic acidosis (markedly elevated lactic acid value) and respiratory acidosis (increased partial pressure of carbon dioxide [P CO2] due to muscle CO2 production). The anion gap is increased due to the lactic acid. In the early phases, venous P CO2 is markedly increased, whereas arterial P CO2 may be normal or only mildly increased (widening of the normal arteriovenous [AV] CO2 dissociation). The same accentuation of normal AV differences also occurs with the PO2 values. Later, arterial blood gas values also show increased PCO2, decreased pH, and decreased PO2. In addition to blood gas changes there typically is greatly increased CK levels (from muscle contraction), and myoglobin appears in the urine. In the later stages there may be hyperkalemia, hypernatremia, muscle edema, pulmonary edema, renal failure, disseminated intravascular coagulation, and shock. The serum calcium level may be normal or increased, but the ionized calcium level is increased.

    Diagnosis. CK elevation without known cause has been proposed as a screening test; there is marked difference of opinion among investigators as to the usefulness of the procedure, either in screening for surgery or in family studies (literative reports vary from 0%-70% regarding the number of persons susceptible to develop MH that have elevated baseline total CK. About 30% may be a reasonable estimate. Also, elevated CK can be caused by a variety of conditions affecting muscle). Likewise, disagreement exists as to the CK isoenzyme associated with abnormality; BB has been reported by some, although the majority found MM to be responsible. However, CK assay is still the most widely used screening test. Muscle biopsy with special in vitro testing of muscle fiber sensitivity to such agents as caffeine and halothane (caffeine-halothane contractive test) is considered a definitive diagnostic procedure but is available only in a few research centers. Since the test should be performed less than 5 hours after the muscle biopsy, it is preferable (if possible) to have this biopsy performed at the institution that will do the test. Microscopic examination of muscle biopsy specimens shows only nonspecific abnormalities, most often described as compatible with myopathy.

  • Gynecomastia

    Gynecomastia is usually defined as enlargement of the male breast. This may be palpable only or may be grossly visible. Either type may be unilateral or bilateral. A small degree of palpable nonvisible gynecomastia is said to be present in about 30%-40% of clinically normal men. Most etiologies of gynecomastia can produce either unilateral or bilateral effects.

    Etiologies. Major etiologies of gynecomastia are presented in the box. In most cases, estrogen (estradiol) is increased relative to testosterone, even if assay values do not demonstrate this. Considering some of the etiologies, some degree of gynecomastia is present in 20%-40% (range, 4%-70%) of boys during puberty but disappears in 1-2 years. Old age demonstrates increased incidence of gynecomastia, possibly due to testicular failure. Testicular failure, either primary (congenital or testicle damage) or secondary (pituitary FSH decrease) can induce increased pituitary production of LH, which, in turn, may induce increased Leydig cell secretion of estradiol. Obesity may result in enhanced conversion of estrogen precursors to estrogen in peripheral tissues. Adrenal hyperactivity, cirrhosis, and chronic renal failure on dialysis therapy may be associated with gynecomastia in some patients due to increased estrogen formation from circulating androgenic precursors. Ten percent to 40% of patients with hyperthyroidism may develop gynecomastia due to increase in testosterone-binding protein. Breast carcinoma in males is rare but is always a possibility in unilateral gynecomastia.

    Laboratory tests. Tests most commonly ordered in patients with gynecomastia are listed in the box. These tests screen for certain possible etiologies. Elevated serum LH levels suggest testicular failure; elevated testosterone levels, Leydig cell tumor; elevated serum estradiol levels, either an estrogen-producing tumor or elevated androgen precursors that are converted to estrogens; serum hCG, testicular or certain other tumors; liver function tests, cirrhosis. There is considerable disagreement among endocrinologists regarding how many tests to order for initial screen and what tests to include in the screen. The box contains tests and procedures frequently mentioned that might be useful to nonendocrinologists. Serum prolactin is usually normal.

    Selected Etiologies of Gynecomastia (% of this Category With Gynecomastia)
    Physiologic etiologies
    Neonatal (60%-90%)
    Pubertal (adolescence) (4%-70%; 25% of overall gynecomastia cases)
    Old age (40%)
    Increased estrogen secretion
    Testicular Leydig cell tumor (25%; 3% of overall gynecomastia cases)
    hCG-secreting tumor
    Hepatoma
    Adrenal cortex tumor
    Increased estrogen precursors
    Obesity
    Cirrhosis (50%)
    Hyperthyroidism (10%-40%)
    Recovery from severe chronic disease
    Renal failure on hemodialysis (50%)
    “Refeeding” gynecomastia after malnutrition (15%)
    Deficiency in androgens (8% of overall gynecomastia cases)
    Testicular failure (primary or secondary)
    Klinefelter’s syndrome (30%-50%)
    Androgen resistance syndromes
    Breast carcinoma
    Medication-induced etiologies (10%-20% of overall gynecomastia cases)
    Testosterone inhibitors (spironolactone, cimetidine) Estrogens
    Androgens
    Others (methyldopa, isoniazid, various psychotropic medications, cytoxins, digitalis, vitamin E
    in large doses, reserpine, ketoconazole)
    Idiopathic (25% of overall gynecomastia cases)

    Possible Workup for Gynecomastia
    Palpation of breast for tumor and examination of testis for tumor
    Medication history
    Inquire about chronic disease; especially dialysis for chronic renal disease, chronic liver disease, or refeeding conditions
    Initial test screen
    Serum estrogen (estradiol)
    Serum free testosterone
    Serum hCG
    Serum LH
    Additional tests (only if indicated)
    Serum androstenedione
    Thyroxine
    Gamma-glutamyltransferase
    Urine 17-KS

  • Female Hirsitism

    Female hirsutism is a relatively common problem in which the overriding concern of the physician is to rule out an ovarian or adrenal tumor. The type and distribution of hair can be used to differentiate physiologic hair growth from nonphysiologic growth (hirsutism). In females there are two types of hair: fine, thin, nonpigmented vellus hair and coarse, curly, pigmented terminal hair. Pubic and axillary terminal hair growth is induced by androgens in the physiologic range. Growth of such hair on the face (especially the chin), sternum area, and sacrum suggests male distribution and therefore excess androgens. Virilization goes one step further and is associated with definite hirsutism, acne, deepening of the voice, and hypertrophy of the clitoris.

    The major etiologies of hirsutism are listed in the box. Hirsutism with or without other evidence of virilization may occur before or after puberty. When onset is prepubertal, the etiology is more often congenital adrenal hyperplasia or tumor. After puberty, PCO disease, Cushing’s syndrome, late-onset congenital adrenal hyperplasia, and idiopathic causes are more frequent. Findings suggestive of tumor are relatively sudden onset; progressive hirsutism, especially if rapidly progressive; and signs of virilization.

    Laboratory tests

    There is considerable disagreement among endocrinologists regarding which tests are most useful in hirsutism. The tests most often used are urine 17-KS, serum testosterone (total or free testosterone), DHEA-S, serum androstenedione, serum dihydrotestosterone, urine 3-a-androstanediol glucuronide, serum LH and FSH, serum prolactin, serum 17-OH-P, urine free cortisol, an ACTH stimulation (“Cortrosyn”) test, and the low-dose overnight dexamethasone suppression test. Each of these tests is used either to screen for one or more etiologies of hirsutism or to differentiate between several possible sources of abnormality. There is considerable disagreement concerning which tests to use for initial screening purposes, with some endocrinologists ordering only two or three tests and others using a panel of five to seven tests. Therefore, it may be worthwhile to briefly discuss what information each test can provide.

    Some Conditions That Produce Hirsutism
    Ovary
    PCO disease
    (Hyperthecosis)
    Ovarian tumor
    Adrenal
    Congenital adrenal hyperplasia (CAH)
    Cushing’s syndrome (nontumor)
    Adrenal tumor
    Testis
    Leydig cell tumor
    Other
    Idiopathic hirsutism
    Hyperprolactinemia
    Starvation
    Acromegaly (rare)
    Hypothyroidism (rare)
    Porphyria (rare)
    Medications
    Phenytoin (Dilantin)
    Diazoxide (Hyperstat)
    Minoxidil(Loniten)
    Androgenic steroids
    Glucocorticosteroids
    Streptomycin

    Urine 17-KS was one of the first tests in hirsutism or virilization. Elevated urine 17-KS levels suggest abnormality centered in the adrenal, usually congenital adrenal hyperplasia (CAH) or adrenal tumor. Ovarian tumors, PCO disease, or Cushing’s syndrome due to pituitary adenoma usually do not produce elevated urine 17-KS levels (although some exceptions occur). However, some cases of CAH fail to demonstrate elevated 17-KS levels (more often in the early pediatric age group and in late-onset CAH). Serum 17-OH-P in neonatal or early childhood CAH and 17-OH-P after ACTH stimulation in late-onset CAH are considered more reliable diagnostic tests. Also, a significant minority (16% in one series) of patients with adrenal carcinoma and about 50% of patients with adrenal adenomas fail to show elevated 17-KS levels. In addition, 17-KS values from adrenal adenoma and carcinoma overlap, although carcinoma values in general are higher than adenoma values. The overnight low-dose dexamethasone test is more reliable to screen for Cushing’s syndrome of any etiology (including tumor) than are urine 17-KS levels, and the 24-hour urine free cortisol assay is a little more reliable than the overnight dexamethasone test (see Chapter 30). At present most endocrinologists do not routinely obtain 17-KS levels.

    Serum testosterone was discussed earlier. Testosterone levels are elevated (usually to mild degree) in more than one half of the patients with PCO disease and in patients with Leydig cell tumors or ovarian testosterone-producing tumors. Elevated serum testosterone suggests a problem of ovarian origin because the ovaries normally produce 15%-30% of circulating testosterone; and in addition, the ovary produces about one half of circulating androstenedione from adrenal DHEA and this androstenedione is converted to testosterone in peripheral tissues. On the other hand, testosterone is produced in peripheral tissues and even in the adrenal as well as in the ovary. Serum testosterone levels therefore may be elevated in some patients with nonovarian conditions such as idiopathic hirsutism. These multiple origins make serum testosterone the current best single screening test in patients with hirsutism. Several investigators have found that serum free testosterone levels are more frequently elevated than serum total testosterone levels in patients with hirsutism, although a lesser number favor total testosterone. Possible false results in total testosterone values due to changes in testosterone-binding protein is another point in favor of free testosterone. Some investigators have reported that serum androstenedione and DHEA-S levels are elevated in some patients with free testosterone values within reference range and that a test panel (e.g., free testosterone, androstenedione, dihydrotestosterone, and DHEA-S) is the most sensitive means of detecting the presence of excess androgens (reportedly with a sensitivity of 80%-90%).

    Dehydroepiandrosterone-sulfate (DHEA-S) is produced entirely in the adrenal from adrenal DHEA. Therefore, elevated DHEA-S levels suggest that at least some excess androgen is coming from the adrenal. The DHEA-S test is also more sensitive for adrenal androgen excess than the urine 17-KS test. A minor difficulty is that a certain number of patients with PCO disease (in which the ovary is supposed to be the source of excess androgen production) and also certain patients with idiopathic hirsutism have some DHEA-S evidence of adrenal androgen production. For example, one third of PCO disease patients in one series were found to have increased DHEA-S levels. Although this was interpreted to mean that some adrenal factor was present as well as the ovarian component, it tends to confuse the diagnosis. Another difficulty is that some infertile women without hirsutism have been reported to have elevated DHEA-S levels. Androstenedione, as noted previously, is a metabolite of adrenal DHEA that is produced about equally in the adrenal and in the ovaries but then reaches peripheral tissues where some is converted to testosterone. Therefore, elevated serum androstenedione levels indicate abnormality without localizing the source. Dihydrotestosterone (DHT) is a metabolite of testosterone and is formed mainly in peripheral tissues. Therefore, elevated DHT levels suggest origin from tissues other than the ovaries or adrenals. Androstanediol glucuronide is a metabolite of DHT and has the same significance. Some investigators report that it is elevated more frequently than DHT. Serum prolactin levels are usually elevated in prolactin-producing pituitary tumors (prolactinoma). These tumors are said to be associated with hirsutism in about 20% of cases. The mechanism is thought to be enhancement of ACTH effect on formation of DHEA. However, it has also been reported that up to 30% of patients with PCO disease have mildly elevated serum prolactin levels (elevated < 1.5 times the upper limit of the reference range). Prolactinomas are more likely in patients with irregular menstrual periods.

    Luteinizing hormone and FSH are useful in diagnosis of PCO disease, which typically (although not always) shows elevated LH levels, with or without elevated FSH levels.

    Urine free cortisol or low-dose overnight dexamethasone test are both standard tests used for diagnosis of Cushing’s syndrome, which is another possible cause of hirsutism.

    Serum 17-OH-P is used to diagnose CAH. Levels of the 17-OH-P specimens drawn between 7 A.M. and 9 A.M. are elevated in nearly all patients with CAH who have symptoms in the neonatal period or in early childhood. However, in late-onset CAH that becomes clinically evident in adolescence or adulthood, 17-OH-P levels may or may not be elevated. The most noticeable symptom of late-onset CAH is hirsutism. Reports indicate that about 5%-10% (range, 1.5%-30%) of patients with hirsutism have late-onset CAH. The most effective test for diagnosis of late-onset CAH is an ACTH (Cortrosyn) stimulation test. A baseline 17-OH-P blood specimen is followed by injection of 25 units of synthetic ACTH, and a postdose specimen is drawn 30 minutes after IV injection or 60 minutes after intramuscular injection. Exact criteria for interpretation are not frequently stated. However, comparison of test results in the literature suggests that an abnormal response to ACTH consists of 17-OH-P values more than 1.6 times the upper limit of the normal 17-OH-P range before ACTH. An “exaggerated” response appears to be more than 3 times the upper limit of the pre-ACTH normal range. In homozygous late-onset CAH there is an exaggerated 17-OH-P response to ACTH. CAH heterozygotes may have a normal response to ACTH or may have an abnormal response to ACTH that falls between a normal response and an exaggerated response.

    Suppression tests, such as a modified dexamethasone suppression test with suppression extended to 7-14 days, have been advocated in the past to differentiate between androgens of adrenal and ovarian origin. Dexamethasone theoretically should suppress nontumor androgen originating in the adrenal. However, studies have shown that the extended dexamethasone suppression test may be positive (i.e., may suppress androgen levels to < 50% of baseline) in some patients with PCO disease, and the test is no longer considered sufficiently dependable to localize the origin of increased androgen to either the adrenal or the ovary alone.

    Radiologic visualization of abdominal organs is helpful if PCO disease, ovarian tumor, or adrenal tumor is suspected. Ultrasound examination of the ovaries and CT of the adrenals are able to detect some degree of abnormality in most (but not all) patients.

    Polycystic ovary (PCO) disease

    PCO disease is considered by some to be the most common cause of female postpubertal hirsutism. It is also an important cause of amenorrhea, oligomenorrhea, and female sterility. PCO disease is defined both clinically and by histopathology. The classic findings at operation are bilaterally enlarged ovaries (about 65%-76% of cases), which on pathologic examination have a thickened capsule and numerous small cysts (representing cystic follicles) beneath the capsule. However, PCO disease is considered to have a spectrum of changes in which there is decreasing ovarian size and a decreasing number of cysts until the ovaries are normal in size (about 25%-35% of cases) with few, if any, cysts but with an increased amount of subcapsular and interstitial stroma. There is also a condition called “hyperthecosis” in which the thecal cells of the stroma are considerably increased and have a luteinized appearance. Some consider hyperthecosis a separate entity; some include it in PCO disease but consider it the opposite end of the spectrum from the polycystic ovary type; and some combine PCO disease and hyperthecosis together under a new name, “sclerocystic ovary syndrome.”

    Clinically, there is considerable variety in signs and symptoms. The classic findings were described by Stein and Leventhal, and the appellation Stein-Leventhal syndrome can be used to distinguish patients with classic findings from patients with other variants of PCO disease. The Stein-Leventhal subgroup consists of women who have bilaterally enlarged polycystic ovaries and who are obese, are hirsute without virilization, have amenorrhea, and have normal urine 17-KS levels. Other patients with PCO disease may lack one or more of these characteristics. For example, only about 70% of patients have evidence of hirsutism (literature range, 17%-95%). Some patients with PCO disease have hypertension, and some have abnormalities in glucose tolerance. A few have virilization, which is said to be more common in those with hyperthecosis.

    Laboratory tests. Laboratory findings in PCO disease are variable, as are the clinical findings. In classic Stein-Leventhal cases, serum testosterone levels are mildly or moderately elevated in about 50% of patients, and other androgen levels are elevated in many patients whose serum testosterone level remains within reference range. Free testosterone levels are elevated more frequently than total testosterone levels. Higher testosterone values tend to occur in hyperthecosis. Most investigators consider the increased androgen values to be derived mainly from the ovary, although an adrenal component has been found in some patients. Although urine 17-KS levels are usually normal, they may occasionally be mildly increased. The most characteristic finding in PCO is an elevated serum LH level with FSH levels that are normal or even mildly decreased. However, not all patients with PCO show this gonadotropin pattern.

    Summary of tests in hirsutism

    Most endocrinologists begin the laboratory investigation of hirsutism with a serum testosterone assay. Many prefer free testosterone rather than total testosterone. The number and choice of additional tests is controversial. Additional frequently ordered screening tests include serum DHEA-S, serum DHT, and the ACTH-stimulated 17-OH-P test. If abnormality is detected in one or more of these tests, additional procedures can help to find which organ and disease is responsible.

  • Female Delayed Puberty and Primary Amenorrhea

    Onset of normal puberty in girls is somewhat variable, with disagreement in the literature concerning at what age to diagnose precocious puberty and at what age to suspect delayed puberty. The most generally agreed-on range of onset for female puberty is between 9 and 16 years. Signs of puberty include breast development, growth of pubic and axillary hair, and estrogen effect as seen in vaginal smears using the Papanicolaou stain. Menstruation also begins; if it does not, the possibility of primary amenorrhea arises. Primary amenorrhea may or may not be accompanied by evidence that suggests onset of puberty, depending on the etiology of the amenorrhea. Some of the causes of primary amenorrhea are listed in the box.

    Some Etiologies of Female Delayed Puberty and Primary Amenorrhea
    Mullerian dysgenesis (Mayer-Rokitansky syndrome): congenital absence of portions of the female genital tract, with absent or hypoplastic vagina. Ovarian function is usually normal. Female genotype and phenotype.
    Male pseudohermaphroditism: genetic male (XY karotype) with female appearance due to deficiency of testosterone effect.
    1. Testicular feminization syndrome: lack of testosterone effect due to defect in tissue testosterone receptors.
    2. Congenital adrenal hyperplasia: defect in testosterone production pathway.
    3. Male gonadal dysgenesis syndromes: defect in testis function.
    a. Swyer syndrome (male pure gonadal dysgenesis): female organs present except for ovaries. Bilateral undifferentiated streak gonads. Presumably testes never functioned and did not prevent mьllerian duct development.
    b. Vanishing testes syndrome (XY gonadal agenesis): phenotype varies from male pseudohermaphrodite to ambiguous genitalia. No testes present. Presumably testes functioned in very early embryologic life, sufficient to prevent mьllerian duct development, and then disappeared.
    c. Congenital anorchia: male phenotype, but no testes. Presumably, testes functioned until male differentiation took place, then disappeared.
    Female sex chromosome abnormalities (Turner’s syndrome—female gonadal dysgenesis— and Turner variants): XO karyotype in 75%-80% of patients, mosaic in others. Female phenotype. Short stature in most, web neck in 40%. Bilateral streak gonads.
    Polycystic (Stein-Leventhal) or nonpolycystic ovaries, not responsive to gonadotropins.
    Deficient gonadotropins due to hypothalamic or pituitary dysfunction.
    Hyperprolactinemia: pituitary overproduction of prolactin alone.
    Effects of severe chronic systemic disease: chronic renal disease, severe chronic GI disease, anorexia nervosa, etc.
    Constitutional (idiopathic) delayed puberty: puberty eventually takes place, so this is a retrospective diagnosis.
    Other: Cushing’s syndrome, hypothyroidism, and isolated GH deficiency can result in delayed puberty.

    Physical examination is very important to detect inguinal hernia or masses that might suggest the testicular feminization type of male pseudohermaphroditism, to document the appearance of the genitalia, to see the pattern of secondary sex characteristics, and to note what evidence of puberty exists and to what extent. Pelvic examination is needed to ascertain if there are anatomical defects preventing menstruation, such as a nonpatent vagina, and to detect ovarian masses.

    Laboratory tests

    Basic laboratory tests begin with chromosome analysis, since a substantial minority of cases have a genetic component. Male genetic sex indicates male pseudohermaphroditism and leads to tests that differentiate the various etiologies. Turner’s syndrome and other sex chromosome disorders are also excluded or confirmed. If there is a normal female karyotype and no chromosome abnormalities are found, there is some divergence of opinion on how to evaluate the other important organs of puberty—the ovaries, pituitary, and hypothalamus. Some prefer to perform serum hormone assays as a group, including pituitary gonadotropins (FSH and LH), estrogen (estradiol), testosterone, prolactin, and thyroxine. Others perform these assays in a step-by-step fashion or algorithm, depending on the result of each test, which could be less expensive but could take much more time. Others begin with tests of organ function. In the algorithm approach, the first step is usually to determine if estrogen is present in adequate amount. Vaginal smears, serum estradiol level, endometrial stimulation with progesterone (for withdrawal bleeding), and possibly endometrial biopsy (for active proliferative or secretory endometrium, although biopsy is considered more often in secondary than in primary amenorrhea)—all are methods to detect ovarian estrogen production. If estrogen is present in adequate amount, this could mean intact hypothalamic-pituitary-ovarian feedback or could raise the question of excess androgen (congenital adrenal hyperplasia, Cushing’s syndrome, PCO disease, androgen-producing tumor) or excess estrogens (obesity, estrogen-producing tumor, iatrogenic, self-medication). If estrogen effect is absent or very low, some gynecologists then test the uterus with estrogen, followed by progesterone, to see if the uterus is capable of function. If no withdrawal bleeding occurs, this suggests testicular feminization, congenital absence or abnormality of the uterus, or the syndrome of intrauterine adhesions (Asherman’s syndrome). If uterine withdrawal bleeding takes place, the uterus can function, and when this finding is coupled with evidence of low estrogen levels, the tentative diagnosis is ovarian failure.

    The next step is to differentiate primary ovarian failure from secondary failure caused by pituitary or hypothalamic disease. Hypothalamic dysfunction may be due to space-occupying lesions (tumor or granulomatous disease), infection, or (through uncertain mechanism) effects of severe systemic illness, severe malnutrition, and severe psychogenic disorder. X-ray films of the pituitary are often ordered to detect enlargement of the sella turcica from pituitary tumor or suprasellar calcifications due to craniopharyngioma. Polytomography is more sensitive for sellar abnormality than ordinary plain films. CT also has its advocates. Serum prolactin, thyroxine, FSH, and LH assays are done. It is necessary to wait 4-6 weeks after a progesterone or estrogen-progesterone test before the hormone assays are obtained to allow patient hormone secretion patterns to resume their pretest status. An elevated serum prolactin value raises the question of pituitary tumor (especially if the sella is enlarged) or idiopathic isolated hyperprolactinemia. However, patients with the empty sella syndrome and some patients with hypothyroidism may have an enlarged sella and elevated serum prolactin levels, and the other causes of elevated prolactin levels (see the box) must be considered. A decreased serum FSH or LH level confirms pituitary insufficiency or hypothalamic dysfunction. A pituitary stimulation test can be performed. If the pituitary can produce adequate amounts of LH, this suggests hypothalamic disease (either destructive lesion, effect of severe systemic illness, or malnutrition). However, failure of the pituitary to respond does not necessarily indicate primary pituitary disease, since severe long-term hypothalamic deficiency may result in temporary pituitary nonresponsiveness to a single episode of test stimulation. Hormone therapy within the preceding 4-6 weeks can also adversely affect test results.

    The box lists some conditions associated with primary amenorrhea or delayed puberty and the differential diagnosis associated with various patterns of pituitary gonadotropin values. However, several cautionary statements must be made about these patterns. Clearly elevated FSH or LH values are much more significant than normal or mildly to moderately decreased levels. Current gonadotropin immunoassays are technically more reproducible and dependable at the upper end of usual values than at the lower end. Thus, two determinations on the same specimen could produce both a mildly decreased value and a value within the lower half of the reference range. In addition, blood levels of gonadotropins, especially LH, frequently vary throughout the day. The values must be compared with age- and sexmatched reference ranges. In girls, the levels also are influenced by the menstrual cycle, if menarche has begun. Second, the conditions listed—even the genetic ones, although to a lesser extent—are not homogeneous in regard to severity, clinical manifestations, or laboratory findings. Instead, each represents a spectrum of patients. The more classic and severe the clinical manifestations, the more likely that the patient will have “expected” laboratory findings, but even this rule is not invariable. Therefore, some patients having a condition typically associated with an abnormal laboratory test result may not show the expected abnormality. Laboratory error is another consideration. Also, the spectrum of patients represented by each condition makes it difficult to evaluate reports of laboratory findings due to differences in patient population, severity of illness, differences in applying diagnostic criteria to the patients, variance in specimen collection protocols, and technical differences in the assays used in different laboratories. In many cases, adequate data concerning frequency that some laboratory tests are abnormal are not available.

    Gonadotropin Levels in Certain Conditions Associated With Primary Amenorrhea or Delayed Puberty
    FSH and LH decreased*
    Hypopituitarism
    Hypothalamic dysfunction
    Constitutional delayed puberty
    Some cases of primary hypothyroidism
    Some cases of Cushing’s syndrome
    Some cases of severe chronic illness
    FSH and LH increased†
    Some cases of congenital adrenal hyperplasia
    Female gonadal dysgenesis
    Male gonadal dysgenesis
    Ovarian failure due to nonovarian agents
    LH increased, FSH not increased‡
    Testicular feminization
    Some cases of PCO disease

    Elevated FSH and LH levels or an elevated LH level alone suggests primary ovarian failure, whether from congenital absence of the ovaries or congenital inability to respond to gonadotropins, acquired abnormality such as damage to the ovaries after birth, or PCO disease.

    An elevated estrogen or androgen level raises the question of hormone-secreting tumor, for which the ovary is the most common (but not the only) location. Nontumor androgen production may occur in PCO disease and Cushing’s syndrome (especially adrenal carcinoma).

    As noted previously, there is no universally accepted single standard method to investigate female reproductive disorders. Tests or test sequences vary among medical centers and also according to findings in the individual patients.

    When specimens for pituitary hormone assays are collected, the potential problems noted earlier in the chapter should be considered.

  • Lipoprotein Phenotyping

    In 1965, Frederickson, Levy, and Lees published an article that caught the attention of the medical world. They divided lipoprotein disorders into five basic “phenotypes,” based primarily on electrophoresis of serum obtained after 10 hours of overnight fasting. The sixth phenotype was added later when type II was split into IIa and IIb. Lipoprotein phenotyping was originally proposed as a means of classifying congenital disorders of lipid metabolism according to the lipoprotein abnormality involved to provide more specific therapy. In this way abnormal serum levels of specific lipids such as cholesterol could be traced to abnormalities in specific lipoprotein groups, which, in turn, could suggest certain congenital or acquired etiologies. In time, however, the original intent and limitations of the system were sometimes forgotten, and treatment was sometimes begun—based on the phenotype suggested by the patient’s lipid profile or lipoprotein electrophoretic pattern—as though the patient had a congenital lipoprotein disease. Congenital disease cannot be treated directly, so therapy is directed against the abnormal lipids. Since congenital disease is present in only a small percentage of persons with abnormal serum lipid values, and since lipid disorders due to acquired conditions are best treated by therapy directed at the condition responsible for the lipid abnormality, some of these persons were not being managed appropriately. In other words, the symptoms (abnormal levels of lipids or lipoproteins) were being treated rather than the underlying etiology.

    Laboratory tests in lipoprotein disorders

    Screening tests for lipoprotein abnormality include determination of serum cholesterol and TG levels plus visual inspection of serum (or plasma) for presence of chylomicrons after the specimen has been kept overnight at refrigerator temperature. After this incubation, chylomicrons will rise to the surface as a creamlike surface layer. If the serum or plasma remains cloudy without formation of a definite surface layer, this represents VLDLs. The specimen should be obtained after a 10- to 12-hour fast. This triad of tests serves not only as a screening procedure but in the majority of cases is sufficient to establish the phenotype. Normal results on all three tests are reasonable evidence against serious lipoprotein disease. However, occasional patients with disease can be missed, due sometimes to laboratory variation, borderline abnormality, or the overlap of normal and abnormal persons in statistically established reference ranges referred to earlier. Lipoprotein electrophoresis and ultracentrifugation are useful in a minority of cases as confirmatory or diagnostic tests. Electrophoresis is helpful in differentiating Frederickson type I from type V disease, some cases of type IIa from IIb, and some cases of type II from type IV. Ultracentrifugation is useful mainly in diagnosis of type III disease. Electrophoresis is not needed in the majority of patients. Lipoprotein phenotyping is done preferably on outpatients rather than hospitalized patients due to the short-term effects of serious illness on lipid metabolism as well as the other factors mentioned in the previous discussion of serum cholesterol measurement. However, screening of hospital inpatients can detect possible abnormality that can be verified later under more basal conditions.

    A short summary of lipoprotein phenotype patterns shows that the presence of a creamlike layer of chylomicrons after overnight incubation of fasting serum in the refrigerator indicates type I or type V. If the serum below the chylomicron layer is clear, this suggests type I; if the serum below the chylomicron layer is cloudy or turbid, this suggests type V. Fasting serum obtained from patients with the other phenotypes does not contain chylomicrons. If fasting serum does not contain chylomicrons, elevation of serum cholesterol levels with normal TG levels suggests type II disease, whereas the reverse suggests type IV disease. If both cholesterol and TG levels are significantly abnormal, the disease may be type II or type III. Type II disease has recently been subdivided into IIa and IIb. Type IIa has increased cholesterol but normal TG. Type IIb has elevated cholesterol and TG. Type III is uncommon. It is similar to IIb in that both cholesterol and TG levels are elevated, but it frequently has a slightly different electrophoretic pattern (broad beta) and always has a peculiar “floating beta” component (a beta-mobility protein that floats at 1.006 density instead of 1.013), which can be demonstrated only by ultracentrifugation. Type IV phenotype has elevated TG and normal cholesterol levels.

    Although the majority of patients can be phenotyped using the triad of biochemical tests, some overlap occurs among the phenotypes because cholesterol is present to some extent in all of the major lipoprotein fractions and because triglyceride is found in both chylomicrons and the VLDL fractions. Also, the laboratory reference range may inadvertently influence a phenotype decision in some cases, depending on whether the upper limit of the reference range was derived from a sample of the local population, obtained from data published in the literature, or structured according to findings in populations with low risk of atherosclerosis.

    Phenotypes I, III, and V are uncommon. Phenotypes II and IV constitute the majority of hyperlipoproteinemias. Type IV is probably more common than type II. Most type IV patients have the acquired form. The majority of type II patients also have the acquired form (the most common etiology being a high-cholesterol diet), but type II is more frequently congenital than type IV.

    Some serum specimens from patients with types IIb, III, or IV disease may have a somewhat cloudy or faintly milky appearance. This must be differentiated from the thicker, creamlike precipitate characteristic of increased chylomicrons.

    Certain considerations affect interpretation of these laboratory results. Patients should be on a normal diet for several days before testing and must be fasting for at least 10 hours before a specimen is drawn. If a test cannot be done the same day, the serum must be refrigerated but not frozen; freezing alters prebeta and chylomicron fractions, although cholesterol and triglyceride determinations can be done. Various diseases may produce certain phenotype patterns or may falsely change one pattern into another. Changes in diet, medications, activity levels, stress, and other factors may alter a mild or borderline abnormality or produce mild abnormality. In addition, the laboratory results have ± 5%-10% built-in variability for technical reasons.

    On electrophoresis, occasional persons display increased prebeta but normal TG levels. If laboratory error is ruled out, these patients may have a congenital variant called “Lp system” or “sinking prebeta.” This is found in up to 10% of the U.S. population and is the same as the lipoprotein group now collectively called Lp(a). Lp(a) was discussed earlier as an independent risk factor for CHD.

    Plasma or serum may be used for lipoprotein analysis. Plasma collected with EDTA is preferred if the specimen cannot be tested the same day. Plasma values for TG are about 2%-4% lower than for serum.

    Two rare diseases display characteristic lipoprotein patterns on electrophoresis. Tangier disease has no alpha peak. Bassen-Kornzweig syndrome (associated with “pincushion” RBCs called acanthocytes, and neurologic abnormalities) lacks a beta peak.

  • Laboratory Tests Used to Assess Risk of Coronary Heart Disease (CHD)

    There has been much interest in the significance of the lipoproteins in atherosclerosis. Large numbers of studies have been carried out, different populations have been examined, various diets have been tried, and endless pages of statistics have been published. Several laboratory assays that have general, but sometimes not unanimous, acceptance as predictors of atherosclerotic risk have emerged from these data. Some of these risk factors include cigarette smoking, fibrinogen (which can be elevated in part due to cigarette smoking but is still a risk factor in nonsmokers), diabetes mellitus, hypertension, and various serum lipids. Discussion follows of laboratory tests currently used to assess the level of coronary heart disease (CHD) risk induced by various risk factors.

    Serum (total) cholesterol. Total serum cholesterol comprises all of the cholesterol found in various lipoproteins. Cholesterol is the major component of LDLs and a minority component of VLDLs and HDLs. Since LDL has consistently been associated with risk of atherosclerosis, and since LDL is difficult to measure, serum total cholesterol has been used for many years as a substitute. There is general agreement that a strong correlation exists between considerably elevated serum cholesterol levels and an increased tendency for atherosclerosis. Disadvantages include the following:

    1. There is considerable overlap between cholesterol values found in populations and individuals at normal risk for atherosclerosis and those at higher risk. This leads to controversy over what values should be established as “normal” for the serum cholesterol reference range. A related problem is a significant difference between the reference range values for cholesterol based on “ideal” populations (i.e., derived from populations with a low incidence of atherosclerosis) compared with reference ranges from populations with a higher incidence of atherosclerosis (e.g., unselected clinically asymptomatic persons in the United States). This has led to objections that data from many persons with significant but subclinical disease are being used to help derive the reference values for populations with higher risk of CHD.

    Whereas the upper limit of statistically derived U.S. values is about 275-300 mg/100 ml (7.2-7.6 mmol/L), some investigators favor 225 mg/100 ml (5.85 mmol/L) as the acceptable upper limit since that is the value representing average risk for CHD in the Framingham study. However, the average risk for CHD in the U.S. population of the Framingham study is higher than the average risk for a low-risk population. The National Institutes of Health (NIH) Consensus Conference on cholesterol in heart disease in 1984 proposed age-related limits based on degree of CHD risk. The NIH Conference guidelines were widely adopted. In some studies, serum cholesterol (as well as triglyceride) reference values are sex related as well as age related.

    To make matters more confusing, many investigators believe that 200 mg/100 ml (5.15 mmol/L) should be considered the acceptable upper limit because that is the approximate upper limit for low-risk populations. The Expert Panel of the National Cholesterol Education Program (NCEP, 1987) chose 200 mg/100 ml without regard to age or sex (Table 22-6). Although the NCEP advocated use of total cholesterol as the basic screening test for CHD risk, they recommended that therapy should be based on LDL cholesterol values.

    The NCEP Guidelines seem to be replacing the NIH Consensus Guidelines. One possible drawback is lack of consideration of HDL cholesterol effects (discussed later), which may be important since HDL is an independent risk factor.

    2. Serum cholesterol can have a within-day variation that averages about 8% (range, 4%-17%) above or below mean values during any 24-hour period (±8% variation represents about ±20 mg/100 ml if the mean value is 250 mg/100 ml).
    3. Day-to-day cholesterol values in the same individual can fluctuate by 10%-15% (literature range, 3%-44%).
    4. Serum cholesterol values may decrease as much as 10% (literature range 7%-15%) when a patient changes from the erect to the recumbent position, as would occur if blood were drawn from an outpatient and again from the same person as a hospital inpatient. Two studies have shown less than 5% average difference between serum cholesterol obtained from venipuncture and from fingerstick capillary specimens in the same patient.
    5. Various lipid fractions are considerably altered during major illnesses. For example, total cholesterol values often begin to decrease 24-48 hours after an acute myocardial infarction (MI). Values most often reach their nadir in 7-10 days with results as much as 30%-50% below previous levels. The effect may persist to some extent as long as 6-8 weeks. In one study not all patients experienced postinfarct cholesterol decrease. Although theoretically one could obtain valid cholesterol results within 24 hours after onset of acute MI, the true time of onset is often not known. Surgery has been shown to induce similar changes in total cholesterol to those following acute MI. HDL cholesterol also temporarily fell in some studies but not in others. Triglyceride levels were relatively unchanged in some studies and increased in others. In bacterial sepsis and in viral infections, total cholesterol levels tend to fall and triglyceride levels tend to increase. Besides effects of illness there are also effects of posture and diet change, stress, medications, and other factors that make hospital conditions different from outpatient basal condition. For example, thiazide diuretic therapy is reported to increase total cholesterol levels about 5%-8% (range, 0%-12%) and decrease HDL cholesterol to a similar degree. However, several studies reported return to baseline levels by 1 year. Certain medications can interfere with cholesterol assay. For example, high serum levels of ascorbic acid (vitamin C) can reduce cholesterol levels considerably using certain assay methods.
    6. Certain diseases are well-known causes of hypercholesterolemia; these include biliary cirrhosis, hypothyroidism, and the nephrotic syndrome. A high-cholesterol diet is another important factor that must be considered.
    7. Total cholesterol becomes somewhat increased during pregnancy. In our hospital, data from 100 consecutive patients admitted for delivery showed 16% with values less than 200 mg/100 ml (5.2 mmol/L); the lowest value was 169 mg/100 ml (4.4 mmol/L). Thirty-five percent were between 200-250 mg/1000 ml (5.2-6.5 mmol/L); 36% were between 250-300 (6.5-7.8 mmol/L); 10% were between 300-350 (7.8-9.1 mmol/L); and 3% were between 350-400 (9.1-10.4 mmol/L), with the highest being 371 (9.6 mmol/L). On retesting several patients 3-4 months after delivery, all had values considerably less than previously, although the degree of decrease varied considerably.
    All of the major lipoprotein fractions, including chylomicrons, contain some cholesterol. Therefore, an increase in any of these fractions rather than in LDL alone potentially can elevate serum total cholesterol values. Of course, for lipoproteins with low cholesterol content the degree of elevation must be relatively great before the total cholesterol value becomes elevated above reference range.

    In summary, according to the NCEP, 200 mg/100 ml (5.15 mmol/L) is the upper acceptable limit for any age. Lipid values obtained during hospitalization may be misleading, and borderline or mildly elevated values obtained on a reasonably healthy outpatient may have to be repeated over a period of time to obtain a more accurate baseline. Changes between one specimen and the next up to 20-30 mg/100 ml (0.52-0.78 mmol/L), or even more—may be due to physiologic variation rather than alterations from disease or therapy.

    Although one would expect cholesterol in food to raise postprandial serum cholesterol values, actually serum cholesterol levels are very little affected by food intake from any single meal. Cholesterol specimens are traditionally collected fasting in the early morning because serial cholesterol specimens should all be drawn at the same time of day after the patient has been in the same body position (upright or recumbent) and because triglyceride (which is greatly affected by food intake) or HDL cholesterol assay are frequently performed on the same specimen.

    Cholesterol assay on plasma using EDTA anticoagulant is reported to be 3.0-4.7 mg/100 ml (0.078-0.12 mmol/L) lower than assay on serum (depending on the concentration of EDTA).

    Low-density lipoprotein cholesterol. The LDL (beta electrophoretic) fraction has been shown in various studies to have a better correlation with risk of atherosclerosis than total serum cholesterol alone, although the degree of improvement is not marked. As noted previously, the NCEP bases its therapy recommendations on LDL values. The major disadvantage of this approach is difficulty in isolating and measuring LDL. The most reliable method is ultracentrifugation. Since ultracentrifugation is available only in a relatively few laboratories and is expensive, it has been standard procedure to estimate LDLs as LDL cholesterol by means of the Friedewald formula. This formula estimates LDL cholesterol from results of triglyceride, total cholesterol, and HDL cholesterol.

    One report suggests that modifying the formula by dividing triglyceride by 6 rather than 5 produces a more accurate estimate of LDL levels. A disadvantage of the Friedewald formula is dependence on results of three different tests. Inaccuracy in one or more of the test results can significantly affect the formula calculations. In addition, the formula cannot be used if the triglyceride level is greater than 400 mg/100 ml (4.52 mmol/L).

    High-density lipoprotein cholesterol. Several large-scale studies have suggested that HDL levels (measured as HDL cholesterol) have a strong inverse correlation with risk of atherosclerotic CHD (the higher the HDL level, the less the risk). HDL seems to be a risk factor that is independent of LDL or total cholesterol. Some believe that HDL cholesterol assay has as good or better correlation with risk of CHD than total or LDL cholesterol. In general, the Framingham study suggested that every 20 mg/100 ml (5.2 mmol/L) reduction of HDL cholesterol corresponds to approximately a doubling of CHD risk. Disadvantages include certain technical problems that affect HDL assay, although methodology is becoming more simple and reliable. These problems include different methods that produce different results and need for two procedure steps (separation or extraction of HDL from other lipoproteins and then measurement of the cholesterol component), all of which produce rather poor correlation of results among laboratories. Ascorbic acid (vitamin C) may interfere (5%-15% decrease) with some test methods but not others. Reliability of risk prediction is heavily dependent on accurate HDL assay, since a relatively small change in assay values produces a relatively large change in predicted risk. HDL values are age and sex dependent. HDL values tend to decrease temporarily after acute MI, as do total serum cholesterol values. Hypothyroidism elevates HDL values and hyperthyroidism decreases them; therefore, in thyroid disease HDL values are not reliable in estimating risk of CHD. The possible effects of other illnesses are not as well known. Certain antihypertensive medications (thiazides, beta-blockers without intrinsic sympathomimetic activity, sympathicolytic agents) decrease HDL by a small but significant degree.

    Since serum total cholesterol and HDL are independent risk factors, some patients may have values for one that suggest abnormality but values for the other that remain within reference limits. As independent risk factors, a favorable value for one does not entirely cancel the unfavorable effect of the other.

    Serum cholesterol/high-density lipoprotein cholesterol ratio. Some investigators use the serum cholesterol/HDL cholesterol ratio as a convenient way to visualize the joint contribution of risk from these important risk factors. The ratio for normal risk is 5, for double risk is 10, and for triple risk is 20. Some believe that the ratio is the best single currently available predictor of CHD risk. Others believe that the ratio does not adequately demonstrate the independent contributions of the two factors and may be misleading in cases in which one or both factors may be abnormal, but the ratio does not suggest the actual degree of abnormality.

    It should be mentioned that some uncertainty exists whether mortality data involving total cholesterol and HDL cholesterol is still valid in persons over age 60, and if so, to what degree.

    Apolipoproteins. Apolipoprotein A (apo A) is uniquely associated with HDL, and measurement of apolipoprotein A1 (apo A1) has been proposed as a better index of atherogenic risk than assay of HDL cholesterol. Apolipoprotein B (apo B) comprises most of the protein component of LDL, which is composed of a core of cholesterol esters covered by a thin layer of phospholipids and free cholesterol around which is wrapped a chainlike molecule of the principal subgroup of apo B known as apo B100. Apo B100 is also the major B apolipoprotein component of VLDL. The apo B subgroup known as apo B48 (produced by the intestine) is a major structural protein in chylomicrons. Some research suggests that apo B may have a role of its own in cholesterol synthesis and that apo B measurement may provide a better indication of atherosclerotic risk than LDL cholesterol measurement. The apo A1/apo B ratio has been reported by some to be the best single predictor of CHD. However, there is some controversy over the role of apoprotein assay in current management of CHD. In my experience the total cholesterol/HDL ratio and the Apo A1/Apo B ratio, done simultaneously, gave approximately the same CHD risk assessment in the great majority of patients. The apoproteins have been quantitated mostly by immunoassay. Apo E4 gene has been proposed as a risk factor for Alzheimer’s disease. Apoprotein assay is still not widely available or widely used, and quality control surveys have shown problems in accuracy between laboratories with one international survey finding within-lab coefficients of variation (CVs) of 5%-10% and between-lab CVs of 15%-30%.

    Triglyceride (TG). Triglyceride (TG) is found primarily in chylomicrons and in VLDLs. In fasting plasma, chylomicrons are usually absent, so TG provides a reasonably good estimate of VLDL. The usefulness of VLDL or TG as an indicator of risk for CHD has been very controversial. The majority opinion in the early 1980s was that TG levels do not of themselves have a strong predictive value for CHD. The majority opinion in the early 1990s cautiously suggests that such an independent role is possible but is not yet unequivocally proven. Several large studies reported a strong correlation between increased TG and increased CHD values. However, when the effect of other risk factors was considered, there was thought to be less evidence of an independent TG role. There is a roughly inverse relationship between TG and HDL levels, so that elevated TG levels tend to be associated with low HDL levels (which are known to be associated with increased risk for CHD). Currently, the major use of TG assay still is to calculate LDL using the Friedewald formula, to help screen for hyperlipidemia, and to help establish lipoprotein phenotypes.

    Other factors that influence TG levels are frequently present. Nonfasting specimens are a frequent source of elevated TG levels. Postprandial TG levels increase about 2 hours (range, 2-10 hours) after food intake with average maximal effect at 4-6 hours. Therefore, a 12- to 16-hour fast is recommended before obtaining a specimen. Within-day variation for triglyceride averages about ± 40% (range, 26%-64%), with between-day average variation about ± 25%-50% (range, 18%-100%). Obesity, severe acute stress (trauma, sepsis, burns, acute MI) pregnancy, estrogen therapy, alcohol intake, glucocorticoid therapy, high-fat diet, and a considerable number of diseases (e.g., diabetes, acute pancreatitis, nephrotic syndrome, gout, and uremia) increase TG levels. Levels more than 1,000 mg/100 ml (11.29 mmol/L) interfere with many laboratory tests, and predispose for acute pancreatitis. There are also certain laboratory technical problems that may falsely decrease or increase TG values. High alkaline phosphatase levels increase TG levels to some degree in all TG methods. All TG methods actually measure glycerol rather than triglyceride, so that glycerol that is not part of TG (from a variety of etiologies) can falsely increase the result unless a “blank” is prepared and subtracted. Increased bilirubin, uric acid, or vitamin C levels interfere with some TG methods.

    Plasma TG fasting values of 250 mg/100 (2.82 mmol/L) were considered to be the upper limit of normal in adults by an NIH Consensus Conference on hypertriglyceridemia in 1993. Fasting values more than 500 mg/100 ml (5.65 mmol/L) were considered definitely abnormal. Most laboratories perform TG assays on serum rather than plasma and apply the NIH cutoff values to the results, although serum values are about 2%-4% less than results obtained from plasma.

    Lipoprotein (a) [Lp(a)] Lipoprotein (a) [Lp(a)] is a lipoprotein particle produced in the liver and composed of two components: one closely resembling LDL in structure which, like LDL, is partially wrapped by a chainlike apo B100 molecule, and an apolipoprotein (a) glycoprotein molecule covalently linked to apo B100 by a single disulfide bond. Apo (a) has a structure rather similar to plasminogen, which is the precursor molecule of the anticoagulant enzyme plasmin. The apo (a) gene is located on the long arm of chromosome 6 next to the gene for plasminogen. However, there are at least 6 alleles (isoforms) of apo (a), so that small variations in the structure and size of apo (a)—and therefore of Lp (a)—may occur. The apo (a) isoforms are inherited in a codominant fashion and Lp(a) is inherited as a autosomal dominant. In Europeans, Lp(a) distribution is considerably skewed toward the lower side of value distribution; while in African Americans there is a gaussian bell-shaped value distribution that is relative to Europeans results in a greater number of elevated values. Familial hypercholesterolemia, chronic renal failure requiring dialysis, the nephrotic syndrome, and postmenopausal decreased estrogen levels (in females) are associated with higher Lp(a) levels. Chronic alcoholism may decrease Lp(a) levels.

    There now are a number of studies indicating that Lp(a) elevation is a very significant independent risk factor for atherosclerosis, especially for CHD and probably for stroke and abdominal aneurisms. About 10% of the general population have elevated levels of Lp(a). Lp(a) values over 30 mg/100 ml increase CHD risk two to threefold. When high levels of LDL and Lp(a) coexist, this raises the relative CHD risk up to fivefold. However, a few studies deny that Lp(a) is an important independent risk factor.

    Lp(a) can be quantitated by a variety of immunoassay methods. Concentration has been reported as total Lp(a) mass; this includes both the lipid (HDL) and protein (apo[A]) components of Lp(a). The majority of the population has values less than 20 mg/dl (0.2 g/L). Elevation above 30 mg/dL (0.3 g/L) is associated with a twofold or more increase in CHD risk. Concentration has also been reported as apo(a) protein mass. Elevation above 0.5-0.7 g/L increases risk for CHD. However, these cutoff points were established in predominately European populations and may not be exactly applicable to other racial populations. There are problems with assay standardization (since currently there is no international standard material) and significant variations between laboratories and various assays. There is also a potential problem because apo(a) and plasminogen have considerable structural similarities, and therefore antibodies against either molecule may have some degree of cross-reaction. Postprandial specimens are reported to be 11%-13% lower than fasting specimens.

    Summary. The most widely used current procedure to estimate risk of coronary heart disease is to obtain serum or plasma total cholesterol levels (as a substitute for LDL assay) and HDL cholesterol levels. If desired, the total cholesterol/HDL ratio can be calculated, and LDL cholesterol levels can be derived from the same data plus TG assay by means of the Friedewald formula. These studies are best performed when the patient is in a basal state. It is important to note that many investigators caution that such studies may be misleading when performed on hospitalized patients, due to the effects of disease and the hospital environment. Accuracy of total cholesterol, HDL, TG, and apolipoprotein measurements is increased if two or preferably three specimens are obtained, each specimen at least 1 week apart (some prefer 1 month apart), each obtained fasting at the same time of the day to establish an average value to compensate for physiologic and laboratory-induced fluctuations in lipoprotein measurements.

  • Laboratory Tests in Neurology

    Most laboratory tests concerned with diagnosis or function of the CNS are discussed earlier in this chapter. The major condition affecting the peripheral nervous system which involves the laboratory is myasthenia gravis.

  • Other Gram-Negative Organisms

    Pseudomonas

    These gramegative rods are not classified with the Enterobacteriaceae, although they may be found normally in the GI tract. The most important is Pseudomonas aeruginosa. Pseudomonas is less common in community-acquired infection than with most of the major Enterobacteriaceae but becomes more frequent in hospital-acquired infections (about 10% of nosocomial infections). The conditions for which it is best known are urinary tract infection, septicemia, pneumonia (especially in patients with cystic fibrosis), extensive burn infection, malignant otitis externa, and infection associated with ocular contact lenses or physical therapy whirlpool tubs. P. aeruginosa is also known for its resistance to many antibiotics and for its high mortality rate.

    In the environment, Pseudomonas organisms live in water or on moist surfaces. In human disease, Pseudomonas has many attributes similar to “opportunistic fungi” in that infection is rare in healthy persons; and even in hospitalized persons, colonization is more common than infection. Infection is most often superimposed on serious underlying diseases such as hematologic or nonhematologic malignancy (especially during chemotherapy), severe burns, wounds, and foreign bodies (tracheostomy, catheter), or in immunocompromised patients. P. aeruginosa is resistant to many of the standard antibiotics and therefore may become a secondary invader after antibiotic therapy for the original infection. This is most frequent in urinary tract infections. Pseudomonas may be found normally on the skin (as well as in the GI tract) and thus is a very important and frequent problem in severe burns. Pseudomonas septicemia is increasing as a complication or a terminal event in patients with malignancy or immunocompromised state. In some tertiary medical centers, Pseudomonas is reported involved in as many as 20% (range, 6%-25%) of bacteremic episodes.

    Calymmatobacterium granulomatis (Donovania granulomatis)

    Granuloma inguinale is a venereal disease caused by a gramegative rod bacterium that has some antigenic similarity to the Klebsiella group. Infection is transmitted by sexual contact. After incubation, an elevated irregular flattened granulomatous lesion develops, usually in or around the medial aspect of the inguinal area or on the labia. The organism is difficult to culture and requires special media, so culture is not usually done. Diagnosis is accomplished by demonstration of the organisms in the form of characteristic Donovan bodies, found in the cytoplasm of histiocytes. The best technique is to take a punch biopsy of the lesion, crush the fresh tissue between two glass slides, and make several smears with the crushed tissue. These smears are air-dried and stained with Wright’s stain. (It is possible to process a biopsy specimen in the routine manner and do special stains on tissue histologic sections, but this is not nearly as effective.) Granuloma inguinale is sometimes confused with lymphogranuloma venereum, a totally different disease, because of the similarity in names and because both are venereal diseases.

    Haemophilus (hemophilus)

    This genus is one of three in the family Pasteurellaceae (the other two are Pasteurella and Actinobacillus). The genus Haemophilus contains several species, most of which are normal nasopharyngeal inhabitants, that on Gram stain are very small gramegative rods (“coccobacilli”). The most important species is Haemophilus influenzae, which is the most common etiology of meningitis between the ages of 2 months and 5 years (about 70% of cases). H. influenzae occasionally produces a serious type of laryngitis (croup) in children known as acute epiglottitis and occasionally is associated with childhood otitis media, sinusitis, meningitis, bacteremia, and pneumonia. H. influenzae infection in adults is far less common than in early childhood, but the same types of diseases may occur. H. influenzae exists in both capsulated and noncapsulated forms. In early childhood, 90%-95% of cases of meningitis or bacteremia are caused by capsulated type B. Non-B encapsulated serotypes and nonencapsulated forms increase in frequency in localized pediatric infection and in adult infection. Currently, most typing of Haemophilus organisms is done with antibodies to the capsular antigens of H. influenzae. “Nontypable” H. influenzae means a noncapsulated strain and cannot be ignored, on this basis alone, as a cause for serious disease. Organisms in the genus Haemophilus require one or both substances called X and V factors. Therefore, the traditional H. influenzae culture plate contains blood agar (supplying the X factor) on which is a small area previously inoculated with S. aureus (“staph streak”), which supplies V factor (“satellite test”). However, other satisfactory culture and identification systems are now available. In addition to culture, latex agglutination tests are available to detect H. influenzae antigen in spinal fluid. These will be discussed in more detail in the chapter on CSF tests. In very limited studies involving patients with infections other than CSF, latex agglutination test results on urine were positive in 92%-100% of cases. Haemophilus influenzae is considered normal flora of the nasopharynx (3%-5% of children over age 6 months) and also sputum (which acquires these organisms as it passes through the oropharynx). Heavy growth or predominance of a single “normal flora” organism increases the suspicion that it may be pathogenic.

    Other members of the Haemophilus genus that deserve special mention are H. aegyptius (Koch-Weeks bacillus), which produces purulent conjunctivitis; and H. ducreyi, which is the etiologic agent of the venereal disease chancroid. Haemophilus aphrophilus is being reported more often in recent years as a pathogen.

    Pasteurella

    The most important organism in this genus is Pasteurella multocida. This is a small gramegative bacillus found normally in the mouth of many (but not all) cats and dogs. Dog bites and either cat bites or cat scratches inoculate the organism, leading to cellulitis and occasionally to osteomyelitis or infection of prosthetic devices. The organism grows on ordinary laboratory media. Isolation and identification is made much easier if the laboratory knows that the specimen is from a dog- or cat-inflicted wound.

    Bordatella

    For a long time these organisms were included in the genus Haemophilus. The most important of this group is Bordatella pertussis, the etiologic agent of pertussis (“whooping cough”). The disease is spread by aerosol droplets and is highly contagious, with attack rates in family members of patients ranging from 50% to over 90%. In one study about two thirds of those infected were asymptomatic. The incubation period averages 7 days (range, 6-20 days). In children there are three clinical stages. The catarrhal stage lasts 1-2 weeks (range, 1-3 weeks), associated with symptoms similar to a mild or moderate viral upper respiratory infection. The paroxysmal stage lasts 2-4 weeks (sometimes more), with paroxysms of coughing alternating with relatively asymptomatic periods being the main symptoms. The convalescent stage usually lasts 1-2 weeks but may persist up to 6 months. The most frequent complication is pneumonia (15% of cases in one study); this is responsible for over 90% of deaths. In adults, clinical symptoms most often consist of chronic cough. In one study, 20%-25% of adults with chronic cough had serological evidence of pertussis.

    Laboratory findings consist mostly of leukocytosis (64% of cases in one study) that averages 21,000/mm3 (21 Ч 109/L) but can reach 70,000/mm3(70 x 109/L). There typically is an absolute lymphocytosis; since young children normally have more lymphocytes than neutrophils on peripheral smear, the percentage of lymphocytes is most often within the age-adjusted reference range for young children. There typically is a significant percentage of small lymphocytes with a clefted or distorted nucleus (12%-56% of the lymphocytes). Most of these are T-lymphocytes. In one study lymphocytosis persisted for more than 1 week in 70% of cases and for more than 2 weeks in 14% of cases. In young children, one study found an abnormal chest x-ray in 42% of patients.

    Options for diagnosis include posterior nasopharyngeal culture, direct tests for antigen on nasopharyngeal swabs, and serologic tests. Material for culture or antigen tests should be obtained from the pharynx at the posterior end of the nose, using a calcium alginate or Dacron-tipped flexible wire swab. Cotton-tipped swabs decrease chances of a positive culture. A positive culture is most likely (80%-90% of cases) during the first and second weeks of the catarrhal stage; during the later part of the third week, and the beginning of the paroxysmal (fourth week) stage, culture positivity falls off rapidly. After the fifth week only 15%-20% of cases are culture-positive. The original (and still useful) culture medium was Bordet-Gengou; however, the newer Regan-Lowe media can increase culture yield by 20% or more. Reported rates of culture diagnosis vary considerably (30%-60%; range, 20%-90%), depending on the stage of disease culture was obtained and the details of culture technique. Culture takes 4-7 days. As noted previously, recovery results over 50% are most likely to be obtained in the first 3 weeks except during epidemics. Direct fluorescent antibody (DFA) tests on posterior nasopharyngeal specimens are less sensitive than culture in the early nontreated stage but may be more sensitive later in clinical illness or after antibiotic therapy. In general, DFA is 50%-90% as sensitive as culture (range, 11%-100% depending on circumstances). False positive rates of 7%-40% have been reported (although some of these may have been true but nonconfirmed positives). Serologic tests are available but difficult to obtain. The most useful clinically are IgG antibodies against pertussis toxin or filamentous hemagglutinins (FHA). Acute and convalescent specimens give best results. Sensitivity of FHA-IgG tests is reported to be 75%-80% (range, 54%-100%).

    Campylobacter

    There are several species within this genus, of which the most important is Campylobacter fetus. This is a gramegative curved or spiral organism that originally was classified as a Vibrio. There are three subspecies (ssp.) of which two may infect humans. One of these is Campylobacter fetus ssp. fetus (formerly, ssp. intestinalis), which causes abortion in sheep and cattle and which can rarely infect humans. It produces disseminated disease without diarrhea, presenting as newborn or infant meningitis and childhood or adult septicemia. It also can produce thrombophlebitis. Patients usually are immunocompromised or have some debilitating disease such as alcoholism, cancer, or renal failure. Diagnosis is made by blood culture in septicemia and by spinal fluid culture in meningitis. Ordinary culture media can be used. The other Campylobacter organism, C. fetus ssp. jejuni, is much more common and infects cattle, dogs, and birds, in addition to humans. Poultry, especially turkeys, have been responsible for some epidemics. C. fetus ssp. jejuni produces enteric infection with diarrhea, which in some areas is responsible for as many cases as Salmonella and Shigella combined. Overall, both children and adults are affected in about equal proportion, although there is variance in different reports. Published studies indicate that C. fetus ssp. jejuni can be isolated from approximately 4%-8% of patients with diarrhea (literature range, 3%-32%).

    Typical symptoms include a prodromal period of 12-24 hours with fever, headache, abdominal pain, and malaise, followed by diarrhea with crampy abdominal pain. Fever often disappears after onset of diarrhea. The diarrhea is sometimes grossly bloody, typically lasts 2-3 days, and usually is self-limited. In some patients it is more prolonged. The severity of illness varies considerably.

    Laboratory tests. Helpful laboratory studies include tests for fecal blood and Gram stain of the feces for WBCs. About two thirds of patients demonstrate gross or occult stool blood (literature range, 60%-90%), and about the same number have segmented neutrophils in the stool. About two thirds of patients have peripheral blood leukocytosis. Fecal culture is the mainstay of diagnosis (blood cultures are usually negative in ssp. jejuni infection). However, routine stool culture will be negative, because the organism is microaerophilic and must be incubated 48-72 hours on special media in special gas mixtures. It grows best at 42°C but will grow at 37°C. Routine laboratories can perform the cultures, but it takes special effort and special techniques. The organism is extremely sensitive to drying. If specimens are sent to an outside laboratory, they should be inoculated into special transport media (not ordinary media) and sent with ice if more than 1 day’s travel is necessary. Gram stain of the feces can demonstrate Campylobacter in about 50% of cases (range, 43%-65%). The organism is gram negative and has different shapes; most typically curved, S-shaped, and “gull winged.” A few reports indicate that 1% aqueous basic fuchsin stain is more sensitive than Gram stain.

    Aeromonas

    The Aeromonas organism, a gramegative rod, is frequently found in water (usually nonchlorinated although chlorinated water is not always safe) and in soil. It infects fish and amphibians as well as humans. Sources of human infection are water; uncooked or poorly cooked meat, poultry, shellfish, and fish; and raw milk. Clinical infection in humans is not common but has been reported in those with traveler’s diarrhea, immunosuppressed patients, and sporadic cases. Asymptomatic infection has been reported in 0.1%-27% of persons examined. Diarrhea and abdominal cramps are the most common symptoms. Persons of all ages can become infected; acute self-limited diarrhea is more common in infants and young children and chronic infection in adults. Occasional extraintestinal disease (osteomyelitis, urinary tract infection, septicemia, and others) has been reported. Diagnosis is most often made by stool culture; enrichment media followed by special selective media is said to give best overall results, although the organisms can grow on standard culture media.

    Helicobacter

    Helicobacter pylori (formerly Campylobacter pylori or pyloridis) is an S-shaped (curved, or “gull-winged” like Campylobacter), small gramegative bacillus found in the mucus covering the gastric mucosa, with the organisms located next to the gastric lining cells of the surface and gastric pits. H. pylori is associated with acute and chronic gastritis in the gastric antrum and is present in about 90% (range, 70%-100%) of patients with duodenal ulcer, in 70%-75% (range, 40%-90%) of patients with gastric ulcer, about 50% (range, 30%-75%) of patients with nonulcer dyspepsia, and about 20%-25% of patients with gastric cancer. Significant H. pylori antibody levels can be detected in about 20%-25% of clinically normal U.S. and European adults (range, 5%-75% depending on age). This suggests that H. pylori infection is often subclinical. Indeed, in patients with clinical infection, biopsy of normal-appearing gastric mucosal areas often contains demonstrable H. pylori organisms. Chronic or recurrent duodenal ulcer is very highly associated with both excess acid production and H. pylori infection. However, one exception is duodenal ulcer due to the Zollinger-Ellison syndrome, in which incidence of H. pylori infection is zero.

    Incidence of H. pylori is age-related; in one study 5% or less of adults age 25-45 had antibodies to H. pylori; 20% of adults age 45-55, 50% of adults 55-65, and 75% of adults over age 65 had the antibodies. African Americans are reported to have about twice the incidence seen in Europeans. Besides antral gastritis, H. pylori is associated to a lesser degree with patchy gastritis in the body of the stomach.

    The traditional gold standard for diagnosis has been culture of gastric mucosal biopsy specimens. This should be placed in 2-3 ml of sterile isotonic saline, plated on enriched media such as chocolate agar or selective media such as Skirrow’s, and incubated 5-7 days at 37°C. However, based on comparison with results of other tests, culture only detects about 75% (range, 50%-95%) of cases. Giemsa stain of gastric mucosa biopsy tissue is reported to detect about 90% of cases (range, 88%-93%), although in my experience it has been less. Warthin-Starry silver stain has a little better sensitivity than Giemsa stain and Gram stain has somewhat less (about 75%; range, 69%-86%). H. pylori has considerable ability to metabolize urea by means of the enzyme urease that forms the basis for several other tests. The urea breath test using radioactive carbon-13 or carbon-14 incorporated into a urea test dose is administered orally and expired air is then tested for radioactivity 20-120 minutes later. This is probably the best test of all those available, with sensitivity in most reports over 95% (range, 90%-100%) and specificity over 95%. In fact, at present it is probably a better gold standard than culture. However, the test is available only in a relatively few large medical centers, is expensive, requires special equipment, and uses long-lived isotopes that are becoming serious disposal problems. Other tests are based on fresh gastric mucosal biopsy tissue placed in a urea-containing medium with some indicator system to signal metabolism of the urea. The best-studied of these is the CLO test; it is reported to have a sensitivity of about 90% (range, 86%-96%).

    Some immunoassays for antibody to H. pylori have become commercially available, mostly in EIA format, which detects IgG, IgA, or IgM anti- body alone or total antibody. In experimental H. pylori infection, an IgM elevation first begins at about 3 weeks, becoming nondetectable about 8 weeks later. IgA and IgG levels rise at about 8-9 weeks after infection, with the IgG level remaining elevated a year or more. The height of elevation does not correlate well with severity of infection. IgM and IgA levels often fall in about 4 weeks after successful treatment, whereas IgG levels are not affected. Most of the antibody assays evaluated in the literature to date have been homemade (which often give better results than commercially available kits); these have reported sensitivity of 80%-100%. Several new commercial kits claim sensitivity of 95% or more. However, some of these sensitivity claims are less because the tests against which the commercial EIA was compared had sensitivity themselves less than 100%. Also, more evaluations must be done to get adequate information about each EIA kit. In general, most current interest seems to be toward IgG antibody. However, this antibody has the disadvantage that it often remains elevated for a year or more after adequate therapy.

    Brucella

    Three members of the Brucella genus produce an uncommon febrile disease known as “brucellosis,” which sometimes must be considered in the differential diagnosis of fever of unknown origin. The Brucella organism is a gramegative coccobacillus with three main species. One species infects cattle, the second one infects goats, and the third is found in swine. Classic brucellosis was most often transmitted to humans by infected milk or milk products. However, persons most likely to contact the infection today in the United States are workers in the meat-processing industry, especially those working with swine. Veterinarians and dairy farmers are also at risk. Clinical symptoms include fever, chills, and myalgia. About 25% of patients develop single-joint arthralgia. Lymph nodes are usually not enlarged. Splenomegaly occurs in about 20% of cases. Some patients develop pneumonia. WBC counts are usually normal or decreased. Blood culture is positive in 30%-50% of cases, but the organisms need added carbon dioxide and grow very slowly on ordinary culture media, so that under ordinary circumstances the brucellae may either not grow at all or the culture bottle is discarded as negative before growth is evident. Special media are available that will assist growth. A slide agglutination test is the most frequent method for diagnosis. Test results greater than 1:80 are suspicious for brucellosis. After recovery, antibody titer elevation lasts 1-2 years.

    Francisella

    Formerly included in the genus Pasteurella, the genus Francisella contains one medically important species, Francisella tularensis, which is the causative agent of tularemia. F. tularensis is a very small gramegative aerobic coccobacillus that requires special media for adequate growth. The major reservoir for human infection in the United States is wild animals, predominantly wild rabbits, and in some cases deerflies or ticks. Most persons who contract the disease are those who handle raw wild rabbit meat. Tularemia may exist in several clinical forms, but the most common symptoms are painful single-area lymphadenopathy (ulceroglandular form, comprising 75%-80% of cases) and prolonged low-grade fever. Much less common is a septicemic form (5%-15% of cases). Pneumonia may occur in 15% or more of either the ulceroglandular or the septicemic forms, especially the septicemic type. Rabbit-associated infection is usually associated with a small ulcerated skin lesion at the place of entry on the hand and also with axillary adenopathy, whereas in tick-associated infection the ulcer is located on the trunk or lower extremities and the lymph nodes affected are most commonly in the inguinal area. About 15% of affected persons lack either the ulcer or both the ulcer and the adenopathy. WBC counts are normal in at least 50% of patients and slightly or mildly elevated in the remainder. The differential cell count is usually normal. Inconsistent elevation of one or more liver function test results is present in about one half of the patients.

    Tularemia must occasionally be considered in the differential diagnosis of fever of unknown origin. The organisms will not grow on standard laboratory culture media. Special media can be obtained and culture performed from lymph node aspiration, but this is rarely done because of an unusually high rate of laboratory technologist infection from the specimens. The standard diagnostic test is a slide agglutination procedure. Titers are said to be negative during the first week of illness and begin to rise at some time during the second week, become maximal in 4-8 weeks, and remain elevated for several years. A fourfold rising titer is necessary to prove acute infection. There is considerable disagreement regarding a single titer level that could be considered presumptive evidence of infection; 1:160 seems to be the least controversial value.

    Vibrios

    Vibrios are gramegative small curved rods. The most important species is Vibrio cholerae, which produces cholera by means of an enterotoxin. The V. cholerae species is subdivided into many serotypes, of which only one, the 01 strain, is associated with epidemic cholera in the United States. A different strain is found in Latin America than in the United States. About 75% of cholera organism infections are asymptomatic, about 20% produce mild to moderate diarrhea, and about 5% produce the severe watery diarrhea ordinarily associated with the name “cholera” that can lead to death from loss of fluid and electrolytes. Humans usually become infected by drinking contaminated water or eating shellfish from contaminated water. Diagnosis has traditionally been made by stool culture. The organism is very sensitive to drying, and if swabs are used, they must be placed in transport media as soon as the specimen is obtained. Also culture has been reported to miss 10%-20% of cases.

    Recently, two stool tests have been developed by the same manufacturer using a monoclonal antibody called COLTA that is claimed to be specific for V. Cholerae 01 strain. CholeraScreen is a coagglutination slide test and CholeraSmart is a tube agglutination test. Both are said to be 95%-100% sensitive compared to culture. Only a few evaluations have been published to date.